Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

CHFR (Checkpoint with fork-head associated and ring finger)

Identity

Other namesFLJ10796
HGNC CHFR
Location 12q24.33
Local_order Genes flanking CHFR in centromere to telomere direction on 12q24.33:
Peroxisomal membrane protein 2 gene (PXMP2)
Hypothetical protein gene (MGC5352)
Golgi autoantigen, golgin subfamily a3 gene (GOLGA3)
Checkpoint with FHA and RING finger gene (CHFR)
Hypothetical gene (GeneID: 90462)
Zinc finger protein 26 gene (ZNF26)
Note CHFR functions as part of an early G2/M checkpoint. This putative early mitotic checkpoint causes a delay in chromosome condensation in response to mitotic stress. Human CHFR gene was originally identified during a search for novel cell cycle checkpoint proteins that have fork-head associated domains. Initial analysis indicated that the CHFR-associated G2/M checkpoint was inactivated in a subset of cancers as demonstrated by high mitotic indices (a high percentage of cells that have condensed chromosomes) in response to exposure to the microtubule poison, nocodazole, due to lack of CHFR expression or CHFR mutations in a neuroblastoma, an osteosarcoma and 2 colon cancer cell lines (4 of 8 different cancer cell lines). Further studies demonstrated loss of or low CHFR expression in various types of cancer cells including those from colon, esophageal, gastric, lung and breast cancers.

DNA/RNA

Description The CHFR gene spans approximately 47 kb and has at least 18 exons (BC012072 vs. NT_024477) as predicted according to Spidey (http://www.ncbi.nlm.nih.gov/spidey/) but experimental confirmation of the genomic structure has not been reported.
Transcription CHFR mRNA is 3189 bp (BC012072). Transcripts that lack exon 2, exon 5 and exon 6 have been detected in various tissues including bone marrow, small intestine, lung, heart, testis, kidney, stomach and lympocytes as well as some cancer cell lines by RT-PCR. Northern blot transcript analysis suggests that limited if any alternative splicing is present in most fetal and adult tissues where CHFR is expressed a prominent 3.2 kb is observed. CHFR mRNA is detected in heart, brain, placenta, lung, liver, muscle, kidney, pancreas by Northern blot analysis.

Protein

Description CHFR encodes a 652 amino acid protein (according to BC012072 nucleotide sequence) with FHA (forkhead associated), RING (really interesting new gene) finger and cysteine rich domains. No alternative isoforms have been described to date.

Domains:

  • FHA domains are present in cell cycle checkpoint genes, transcription factors, protein kinases and have roles in protein-protein interactions with specificity for phosphorylated targets. The three dimensional structure of CHFR suggests that CHFR may be able to recognize as of yet unidentified phosphorylated targets.
  • RING finger domains are found in ubiquitin ligases. Ubiquitin ligases attach ubiquitin to target proteins during a cascade of enzymatic reactions. RING finger domains are present in a variety of proteins (e.g. Anaphase promoting complex, APC, Cbl family proteins, MDM2) implicated in cancer.
  • Function CHFR induces an early G2/M checkpoint in response to mitotic stress. Cell lines expressing wild-type CHFR exhibit low mitotic index (percentage of cells with condensed chromosomes) and delayed entry into metaphase when centrosome separation is inhibited by mitotic stress. In contrast, cancer cell lines lacking CHFR function enter metaphase without delay and demonstrate higher mitotic indices compared to the CHFR expressing cell lines.

    In vitro studies suggest that the RING finger domain in CHFR also facilitates ubiquitin ligase function and that it is essential for checkpoint function of CHFR. In vitro Xenopus extract experiments suggested that CHFR specifically targets PLK1 (polo-like kinase 1) for degradation when extracts are supplemented with high ubiquitin concentrations. Thus, according to this in vitro model, CHFR is able to halt cell cycle progression early in mitosis by degrading PLK1, a major player for the activation of mitosis promoting factor.

    However, a more recent study suggests that the ubiquitin ligase function of CHFR may be different than the current in vitro model and that instead of Lys48 ubiquitination, CHFR may link ubiquitin to target protein or proteins via Ly63 due to its interaction with the heteromeric ubiquitin conjugating enzyme complex, Ubc13-Mms2. In the canonical ubiquitin/proteasome pathway, Lys48 is a signal for degradation of target proteins whereas Lys63 ubiquitination functions as a non-proteolytic tag for protein targets. The mechanistic roles of Lys63 are not understood but this type of ubiquitination is involved in error-free post-replicative DNA repair and NF-kB signal transduction.

    Homology M.musculus 5730484M20Rik RIKEN cDNA 5730484M20 gene, R.norvegicus LOC288734 similar to RIKEN cDNA 5730484M20, budding yeast proteins, Dma1 and Dma2 are 58% identical to each other and are possible homologs of human CHFR. Dma1 and Dma2 have roles in spindle formation and formation of septin ring during cytokinesis.

    Mutations

    Germinal No germline mutations have been reported yet.
    Somatic A panel of 53 lung carcinomas has been screened with matching normal tissue and 3 mutations were found, one of which was associated with loss of heterozygosity. Mutations found in patient samples were: C587T, G695C (both between the FHA and RING domains) and T1697C (in the C-terminal cysteine rich region of CHFR). However, no correlation was found with a specific diagnosis or stage of the disease in the patients.

    Implicated in

    Disease Lack or decreased expression of CHFR is observed in a variety of cancer cell lines and tumors. Hypermethylation of the CHFR promoter is detected in a variety of cancer cell lines including esophageal, colon, lung, osteosarcoma, central nervous system, leukemic and primary tumors of the colon, lung and esophagus suggesting that decrease or loss of expression is associated with the hypermethylation of CHFR promoter. Primary cancers of various origin (11 of 30 (37%) colon adenocarcinomas, 2 of 20 (10%) primary non-small lung carcinomas, 7 of 37 (19%) lung cancer specimens, 25 of 63 (40%) primary colorectal cancers, 27 of 51 (53%) colorectal adenomas, 16 of 54 (30%) head and neck cancers also demonstrate hypermethylation of CHFR promoter. CpG methylation and silencing of CHFR depends on the activities of two DNA methyltransferases, DNMT1 and DNMT3b since their inactivation restores CHFR expression.
    Cytogenetics A lung cancer patient sample demonstrates loss of heterozygosity for a CA repeat located on a BAC that contains the CHFR gene. Several other cancers demonstrate allelic imbalance involving chromosome band 12q24 but specific analysis of CHFR in these samples has not been investigated.
    Abnormal Protein None described
    Oncogenesis A wide variety of cancer cell lines and tumor samples demonstrate lack of or low CHFR expression associated with abnormal checkpoint responses after treatment with nocodazole. Currently it is unclear which in vivo events trigger activation of the CHFR-associated G2/M checkpoint and which proteins interact with or regulate CHFR. The fact that nocodazole is a microtubule depolymerizing agent that can activate the checkpoint before the formation of microtubule spindles suggests that early events dependent on microtubules such as centrosome duplication and separation may be monitored by this checkpoint.
      

    External links

    Nomenclature
    HGNCCHFR   20455
    Entrez_GeneCHFR  55743  checkpoint with forkhead and ring finger domains
    Cards
    AtlasCHFRID526
    GeneCardsCHFR
    EnsemblCHFR [Search_View]   ENSG00000072609 [Gene_View]
    GenatlasCHFR
    GeneLynxCHFR
    eGenomeCHFR
    euGene55743
    Genomic and cartography
    GoldenPathCHFR  -  12q24.33   chr12:131927011-131974257 -  12q24.33   [Description]    (hg18-Mar_2006)
    EnsemblCHFR - 12q24.33 [CytoView]
    NCBIMapview
    OMIMDisease map [OMIM]
    HomoloGeneCHFR
    Gene and transcription
    GenbankAF170724 [ ENTREZ ]
    GenbankAK001658 [ ENTREZ ]
    GenbankAK027687 [ ENTREZ ]
    GenbankAK054917 [ ENTREZ ]
    GenbankAK090948 [ ENTREZ ]
    RefSeqNM_018223 [ SRS ]    NM_018223 [ ENTREZ ]
    RefSeqAC_000055 [ SRS ]    AC_000055 [ ENTREZ ]
    RefSeqAC_000144 [ SRS ]    AC_000144 [ ENTREZ ]
    RefSeqNC_000012 [ SRS ]    NC_000012 [ ENTREZ ]
    RefSeqNT_024477 [ SRS ]    NT_024477 [ ENTREZ ]
    RefSeqNW_001838068 [ SRS ]    NW_001838068 [ ENTREZ ]
    RefSeqNW_925428 [ SRS ]    NW_925428 [ ENTREZ ]
    AceViewCHFR AceView - NCBI
    UnigeneHs.656770 [ SRS ]    Hs.656770 [ NCBI ]     HS656770 [ spliceNest ]
    Fast-db15147 (alternative variants)
    Protein : pattern, domain, 3D structure
    SwissProtQ96EP1 [ SRS]    Q96EP1 [ EXPASY ]     Q96EP1 [ INTERPRO ]     Q96EP1 [ UNIPROT ]
    PrositePS50006 FHA_DOMAIN [ SRS ]    PS50006 FHA_DOMAIN [ Expasy ]
    PrositePS00518 ZF_RING_1 [ SRS ]    PS00518 ZF_RING_1 [ Expasy ]
    PrositePS50089 ZF_RING_2 [ SRS ]    PS50089 ZF_RING_2 [ Expasy ]
    InterproIPR000253 FHA [ SRS ]    IPR000253 FHA [ EBI ]
    InterproIPR001841 Znf_RING [ SRS ]    IPR001841 Znf_RING [ EBI ]
    InterproIPR013083 Znf_RING/FYVE/PHD [ SRS ]    IPR013083 Znf_RING/FYVE/PHD [ EBI ]
    CluSTrQ96EP1
    PfamPF00498 FHA [ SRS ]    PF00498 FHA [ Sanger ]    pfam00498 [ NCBI-CDD ]
    PfamPF00097 zf-C3HC4 [ SRS ]    PF00097 zf-C3HC4 [ Sanger ]    pfam00097 [ NCBI-CDD ]
    SmartSM00240 FHA [EMBL]
    SmartSM00184 RING [EMBL]
    BlocksQ96EP1
    PDB1LGP [ SRS ]    1LGP [ PdbSum ],   1LGP [ IMB ]   1LGP [ RSDB ]
    PDB1LGQ [ SRS ]    1LGQ [ PdbSum ],   1LGQ [ IMB ]   1LGQ [ RSDB ]
    Protein Interaction databases
    DIPQ96EP1
    IntActQ96EP1
    Polymorphism : SNP, mutations, diseases
    OMIM605209    [ map ]   
    GENECLINICS605209
    SNPCHFR [dbSNP-NCBI]  
    SNPNM_018223 [SNP-NCI]  
    SNPCHFR [GeneSNPs - Utah]  CHFR] [HGBASE - SRS]
    HAPMAPCHFR [HAPMAP]  
    COSMICCHFR [Somatic mutation (COSMIC-CGP-Sanger)]  
    HGMDCHFR
    General knowledge
    Family BrowserCHFR [UCSC Family Browser]
    SOURCENM_018223
    SMDHs.656770
    SAGEHs.656770
    Enzyme6.3.2.- [ Enzyme-Expasy ]   6.3.2.- [ Enzyme-SRS ]   6.3.2.- [ IntEnz-EBI ]   6.3.2.- [ BRENDA ]   6.3.2.- [ KEGG ]   6.3.2.- [ WIT ]
    GOprotein polyubiquitination [Amigo]  protein polyubiquitination
    GOmitotic cell cycle [Amigo]  mitotic cell cycle
    GOubiquitin-protein ligase activity [Amigo]  ubiquitin-protein ligase activity
    GOprotein binding [Amigo]  protein binding
    GOcellular_component [Amigo]  cellular_component
    GOnucleus [Amigo]  nucleus
    GOubiquitin-dependent protein catabolic process [Amigo]  ubiquitin-dependent protein catabolic process
    GOmitosis [Amigo]  mitosis
    GOmitotic cell cycle checkpoint [Amigo]  mitotic cell cycle checkpoint
    GOzinc ion binding [Amigo]  zinc ion binding
    GOligase activity [Amigo]  ligase activity
    GOmetal ion binding [Amigo]  metal ion binding
    GOcell division [Amigo]  cell division
    KEGGTryptophan metabolism
    PubGeneCHFR
    TreeFamCHFR
    CTD55743 [Comparative ToxicoGenomics Database]
    Other databases
    Probes
    ProbeCHFR Related clones (RZPD - Berlin)
    PubMed
    PubMed33 Pubmed reference(s) in LocusLink

    Bibliography

    Conducting the mitotic symphony.
    Cortez D, Elledge SJ
    Nature. 2000 ; 406 (6794) : 354-356.
    PMID 10935617
     
    Chfr defines a mitotic stress checkpoint that delays entry into metaphase.
    Scolnick DM, Halazonetis TD
    Nature. 2000 ; 406 (6794) : 430-435.
    PMID 10935642
     
    Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity.
    Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, Zhou BB
    Cancer research. 2002 ; 62 (6) : 1797-1801.
    PMID 11912157
     
    The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition.
    Kang D, Chen J, Wong J, Fang G
    The Journal of cell biology. 2002 ; 156 (2) : 249-259.
    PMID 11807090
     
    Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers.
    Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y, Takahashi T
    Oncogene. 2002 ; 21 (15) : 2328-2333.
    PMID 11948416
     
    Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer.
    Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, Kudo J, Terashita Y, Konishi S, Sugiura H, Fujii Y
    Carcinogenesis. 2002 ; 23 (10) : 1695-1699.
    PMID 12376479
     
    Crystal structure of the FHA domain of the Chfr mitotic checkpoint protein and its complex with tungstate.
    Stavridi ES, Huyen Y, Loreto IR, Scolnick DM, Halazonetis TD, Pavletich NP, Jeffrey PD
    Structure (London, England : 1993). 2002 ; 10 (7) : 891-899.
    PMID 12121644
     
    FHA: a signal transduction domain with diverse specificity and function.
    Tsai MD
    Structure (London, England : 1993). 2002 ; 10 (7) : 887-888.
    PMID 12121642
     
    Chfr inactivation is not associated to chromosomal instability in colon cancers.
    Bertholon J, Wang Q, Falette N, Verny C, Auclair J, Chassot C, Navarro C, Saurin JC, Puisieux A
    Oncogene. 2003 ; 22 (55) : 8956-8960.
    PMID 14654793
     
    The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains.
    Bothos J, Summers MK, Venere M, Scolnick DM, Halazonetis TD
    Oncogene. 2003 ; 22 (46) : 7101-7107.
    PMID 14562038
     
    Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer.
    Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS
    Carcinogenesis. 2003 ; 24 (1) : 47-51.
    PMID 12538348
     
    Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer.
    Mariatos G, Bothos J, Zacharatos P, Summers MK, Scolnick DM, Kittas C, Halazonetis TD, Gorgoulis VG
    Cancer research. 2003 ; 63 (21) : 7185-7189.
    PMID 14612512
     
    Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
    Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K
    Cancer research. 2003 ; 63 (24) : 8606-8613.
    PMID 14695171
     
    Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
    Shtivelman E
    Molecular cancer research : MCR. 2003 ; 1 (13) : 959-969.
    PMID 14638868
     
    Epigenetic inactivation of CHFR in human tumors.
    Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K, Tokino T
    Proceedings of the National Academy of Sciences of the United States of America. 2003 ; 100 (13) : 7818-7823.
    PMID 12810945
     
    CHFR-associated early G2/M checkpoint defects in breast cancer cells.
    Erson AE, Petty EM
    Molecular carcinogenesis. 2004 ; 39 (1) : 26-33.
    PMID 14694445
     
    Functional characterization of Dma1 and Dma2, the budding yeast homologues of Schizosaccharomyces pombe Dma1 and human Chfr.
    Fraschini R, Bilotta D, Lucchini G, Piatti S
    Molecular biology of the cell. 2004 ; 15 (8) : 3796-3810.
    PMID 15146058
     
    REVIEW articlesautomatic search in PubMed
    Last year publicationsautomatic search in PubMed

    Search in all EBI   NCBI

    Contributor(s)

    Written06-2004Ayse E Erson, Elizabeth M Petty
    Biology Department, Room: 141, Middle East Technical University, Ankara 06531, Turkey

    Citation

    This paper should be referenced as such :
    Erson AE, Petty EM . CHFR (Checkpoint with fork-head associated and ring finger). Atlas Genet Cytogenet Oncol Haematol. June 2004 .
    URL : http://AtlasGeneticsOncology.org/Genes/CHFRID526.html

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Mon Aug 11 21:12:59 2008


    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    j.l.huret@chu-poitiers.fr.